



## Eukarÿs winner of the Gene Therapy Challenge of the Startups meet Pharma 2020 competition

Evry-Courcouronnes, Sunday, June 14, 2020,

Eukarÿs is pleased to announce today that it has won the Bayer challenge: disruptive gene therapies, cell therapies and innovative delivery technologies of the Startups meet Pharma 2020 competition organized by EIT Health. Eukarÿs will work in the coming months with representatives of different companies in the pharmaceutical industry on the improvement and implementation of its synthetic gene therapy solution - recently extended to synthetic gene vaccination.

### **About Eukarÿs:**

Eukarÿs is a French biotechnology company from the Biocluster of the Genopole of Evry which is developing a radically innovative non-viral approach to synthetic gene therapy, recently extended to synthetic gene vaccination. Synthetic gene therapy is designed to be usable for the majority of human diseases and to provide solutions to the challenges of safety, tolerance, immunogenicity and production costs faced by existing gene therapy technologies. It operates the first, and to date the only, eukaryotic artificial expression system called C3P3 invented and patented by Eukarÿs, as well as gene assembly technologies invented and developed by Eukarÿs.